About Us>Medical Advisory Board > Pallav K. Mehta, MD

Pallav K. Mehta, MD

Medical Director, Reimagine Care; Assistant Professor of Medicine, MD Anderson Cancer Center at Cooper

Pallav Mehta

Highlights

Connect

Cooper Health
featured_paragraph

Pallav Mehta, MD, is a medical oncologist/hematologist with expertise and interest in breast cancer and integrative oncology and is board certified in medical oncology, hematology, and integrative medicine with previous board certification in internal medicine.

general_content

Dr. Mehta currently serves as an assistant professor of medicine at Cooper Medical School, Rowan University and as director of integrative oncology and practice development at MD Anderson Cancer Center at Cooper in Camden, New Jersey. He is also chief of the division of hematology/oncology and director of oncology for Redeemer Health in partnership with MD Anderson Cancer Center at Cooper.

In February of 2023, Dr. Mehta accepted a position as the medical director of Reimagine Care, a tech-enabled, human-led startup company transforming the cancer care experience for patients and the care team. He continues to maintain his breast cancer clinic on a more limited basis.

While being published in the medical literature and serving as principal investigator on several active clinical trials, Dr. Mehta also co-authored After Cancer Care: The Definitive Self-Care Guide to Getting and Staying Well for Patients after Cancer, which provides evidence-based information to patients regarding lifestyle intervention after cancer treatment. The book is an international bestseller and has been translated into 3 languages.

Dr. Mehta has received over 30 Castle Connolly “Top Doc” distinctions regionally and nationally in cancer care, women’s health, breast cancer and integrative oncology.

quote_style_1

The relationship that is developed between a patient and their oncologist is one that is unique in all of medicine. I truly appreciate and enjoy the opportunity to guide my patients through what is often a frightening and life-changing experience. I firmly believe in utilizing standard of care and cutting-edge cancer therapies, while also understanding the importance of the patient as a human being, incorporating topics such as optimizing nutrition or exercise with every patient I meet. I am always grateful that this wonderful profession provides me with personal and professional fulfillment at every level.

Dr. Pallav Mehta

video
3_column_content

Experience & accolades

Expertise

  • Medical oncology
  • Hematology

Education

Experience

Awards & distinctions

Professional memberships & board positions

Publications

contributions_carousel

Contributions

Next-generation sequencing (NGS) tests

11/18/24 | BY: Pallav K. Mehta

Next-generation sequencing (NGS) is a testing technology that uses computers to look at hundreds of genes in cancer cells. The results can help guide treatment decisions.

Read More
 | 7 Min. Read

Treatment for metastatic breast cancer

10/14/24 | BY: Douglas Yee, Pallav K. Mehta

The goal of metastatic breast cancer treatment is to manage the disease while limiting side effects. Learn about available treatments and when they are used.

Read More
 | 22 Min. Read |

Targeted therapy for hormone receptor-positive breast cancer

10/14/24 | BY: Sameer Gupta, Pallav K. Mehta

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy, including CDK 4/6 inhibitors.

Read More
 | 12 Min. Read |

Clinical trials

09/26/24 | BY: LBBC Staff, Pallav K. Mehta

Clinical trials are research studies carried out in people. They evaluate new therapies and compare the new treatments to current ones.

Read More
 | 13 Min. Read |

FDA approval programs

09/26/24 | BY: Pallav K. Mehta

Studying medicine effects takes years. FDA reviews extend the process, but offers programs to expedite vital medicines for those in need.

Read More
 | 8 Min. Read

Clinical trials for MBC

09/26/24 | BY: Pallav K. Mehta

There are many reasons you might change treatments for metastatic breast cancer. If you and your doctors find that one medicine isn’t right for you anymore, you’ll talk about other therapies that are available.

Read More
 | 7 Min. Read |

HER2-positive or HER2-low

05/28/24 | BY: Pallav K. Mehta

HER2-positive or HER2-low breast cancer is caused by a genetic mutation in the HER2 gene. Learn more about the causes and treatment options for this type of breast cancer.

Read More
 | 14 Min. Read |

HER2-Positive MBC

05/24/24 | BY: Pallav K. Mehta

Learn more about metastatic breast cancer that is HER2-positive and how it can be treated with targeted therapy.

Read More
 | 7 Min. Read |

Biomarker testing

04/15/24 | BY: Pallav K. Mehta

A biomarker is a protein, gene mutation, or other substance that can be tested using a sample of cancer tissue or blood. Biomarker test results can help you and your doctor better understand your cancer and treatment options.

Read More
 | 22 Min. Read |

Hormone receptor-positive MBC

07/26/23 | BY: Pallav K. Mehta

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More
 | 6 Min. Read |

How breast cancer is staged

04/19/23 | BY: Pallav K. Mehta

Breast cancer staging (0-5) describes the extent of the cancer in the breast and body. Learn more about what your staging diagnosis may mean for you.

Read More
 | 21 Min. Read |

Trastuzumab deruxtecan

12/19/22 | BY: Pallav K. Mehta

Trastuzumab deruxtecan (Enhertu) is an antibody drug conjugate approved to treat people with metastatic, HER2-positive, hormone receptor-negative breast cancer that has grown after at least two past treatments.

Read More
 | 4 Min. Read

Breast cancer treatment timeline

05/24/22 | BY: Pallav K. Mehta

Breast cancer treatment can vary greatly from person to person. Learn more about the average timelines for diagnostics, testing, treatment, and recovery.

Read More
 | 16 Min. Read |

Metastatic breast cancer symptoms

11/12/21 | BY: Pallav K. Mehta

Metastatic breast cancer can cause a range of symptoms, and not every person experiences them in exactly the same way.

Read More
 | 10 Min. Read |

COVID-19 vaccine boosters for people in breast cancer treatment, with Pallav Mehta, MD

08/25/21 | BY: Pallav K. Mehta

Living Beyond Breast Cancer CEO Jean A. Sachs, MSS, MLSP, speaks with medical oncologist Pallav Mehta, MD, about who is eligible for a COVID-19 booster shot, whom to ask if you think you should get a booster, and how medical centers are adapting to recommendations.

 

Read More
 | 14 Min. Read

Getting a second opinion

02/26/21 | BY: Pallav K. Mehta

Learn about the process of getting a second opinion on your breast cancer diagnosis and the many reasons it could be helpful on your journey.

Read More
 | 13 Min. Read |

Symptoms

11/12/20 | BY: Pallav K. Mehta

Signs and symptoms are two different things. Learn about the breast cancer indications doctors look for, and why mammograms are so important.

Read More
 | 8 Min. Read |

Healthcare provider perspective: It’s a marathon

08/23/19 | BY: Madison Hughes, Pallav K. Mehta

Pallav K. Mehta, MD, spoke with LBBC about the changes he’s seen in 15 years of treating metastatic hormone receptor-positive breast cancer, and what people should know about their diagnosis and treatment.

Read More
 | 13 Min. Read

Inflammatory

08/20/19 | BY: Pallav K. Mehta

Inflammatory breast cancer, or IBC, is an aggressive type of invasive breast cancer that usually doesn’t form a lump.

Read More
 | 8 Min. Read |

Being in treatment for life

08/19/19 | BY: Pallav K. Mehta

A diagnosis of metastatic breast cancer is different because it means you will actively deal with breast cancer for the rest of your life.

Read More
 | 5 Min. Read

Ado-trastuzumab emtansine

07/16/19 | BY: Pallav K. Mehta

Ado-trastuzumab emtansine (Kadcyla) is the targeted therapy trastuzumab (Herceptin) with the chemotherapy medicine emtansine attached. It may also be called T-DM1.

Read More
 | 5 Min. Read

Lapatinib

03/19/18 | BY: Pallav K. Mehta

Lapatinib (Tykerb) is targeted therapy used with the chemotherapy pill capecitabine (Xeloda) or the aromatase inhibitor letrozole (Femara) to treat HER2-positive metastatic breast cancer.

Read More
 | 5 Min. Read |

DCIS

08/31/15 | BY: Pallav K. Mehta

In ductal carcinoma in situ, also called DCIS, abnormal cells are found in the lining of the milk ducts, the tubes that carry milk to the nipple. It is also called intraductal carcinoma.

Read More
 | 6 Min. Read |

Goals of treatment

08/31/15 | BY: Pallav K. Mehta

The goal of treatment in metastatic breast cancer is to work with your healthcare team to prevent or slow progression of the disease while easing your symptoms and treatment side effects.

Read More
 | 5 Min. Read |

Making treatment decisions throughout your care

08/31/15 | BY: Pallav K. Mehta

There are many reasons you might change treatments for metastatic breast cancer. If you and your doctors find that one medicine isn’t right for you anymore, you’ll talk about other therapies that are available.

Read More
 | 6 Min. Read